FirstWord

Proceeds from the series B will be used to move the T-cell receptor (TCR)-CD3 bispecific programmes TTX-008 and TTX-018 into clinical development.

The financing will help the biotech commence clinical trials for ATX-011 in essential thrombocythaemia, while also driving forward additional programmes.

The multi-kinase inhibitor CBT-001 improved conjunctival hyperaemia and reduced lesion-length progression versus vehicle in patients with the conjunctival condition.

The RAS inhibitor, approved for certain patients with pancreatic cancer, brought in close to $200 million in sales for its first five weeks on the market.

The biotech's shares gained 28% on the takeout rumour Wednesday.

Anthony Ford, PhD, CuraSen’s President and Chief Scientific Officer, to Deliver the Burnstock Plenary LectureSAN CARLOS, Calif.--(BUSINESS WIRE)-- CuraSen Therapeutics, Inc., a biopharmaceutical compa...

Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from 5.6...

Preclinical studies demonstrate 100% survival and sustained bile flow in an experimental model of biliary atresia following treatment with SRT-015SEATTLE, Nov. 5, 2026 /PRNewswire/ -- Seal Rock Therap...

Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA ...

Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on trackResults from...